Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly, GSK, Otsuka Pharmaceutical and Pfizer
Research and Markets has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering.
Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which, in turn, can result in an increase in the overall consumption of medicines.
According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market.
Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disorder Overview
08. Market Landscape
09. Market Segmentation by Mechanism of Action
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Companies Mentioned:
Abbott Laboratories
Actavis
AstraZeneca
Aurobindo Pharma
Bristol-Myers Squibb
Dr. Reddy's Laboratories
Eli Lilly and Company
GlaxoSmithKline
H. Lundbeck
Janssen Pharmaceuticals
Lupin
Novartis
Otsuka Pharmaceutical
Pfizer
Pierre Fabre
Shire
Somerset Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Valeant Pharmaceuticals
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance